Market Place
Sourcing Support
TFF Pharmaceuticals Announces It Will Wind Down Operations
14 Nov 2024 //
GLOBENEWSWIRE
TFF Pharmaceuticals` Technology Generates Superior Formulations
26 Sep 2024 //
GLOBENEWSWIRE
TFF Partners With Emory And BARDA For Inhaled mRNA Flu And COVID Treatment
11 Sep 2024 //
GLOBENEWSWIRE
TFF Announces Positive Data For Intranasal Flu Vaccine
10 Sep 2024 //
GLOBENEWSWIRE
TFF Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
03 Sep 2024 //
GLOBENEWSWIRE
TFF Pharmaceuticals Reports Q2 2024 Financial Results And Corporate Update
14 Aug 2024 //
GLOBENEWSWIRE
TFF Pharma Reports Positive Outcomes From Tacrolimus Powder Trial
06 Aug 2024 //
GLOBENEWSWIRE
TFF Pharmaceuticals Engages Outcome Capital As Advisor
26 Jun 2024 //
GLOBENEWSWIRE
TFF provides regulatory update on Tacrolimus Inhalation Powder (TFF TAC)
24 Jun 2024 //
GLOBENEWSWIRE
Tff Leidos Biodefense Countermeasures: Darpa Preclinical Program Advanced
23 May 2024 //
GLOBENEWSWIRE
TFF, Cleveland Clinic Advance Universal Flu Vaccine Candidates
20 May 2024 //
GLOBENEWSWIRE
TFF Pharmaceuticals, Cleveland Clinic to Advance Multiple Influenza Vaccines
20 May 2024 //
CONTRACT PHARMA
TFF Provides Update On TAC Inhalation Powder Lung Transplant Rejection Trial
15 May 2024 //
GLOBENEWSWIRE
TFF Pharma Reports Q1 Financial Results, Corporate Update
14 May 2024 //
GLOBENEWSWIRE
TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering
01 May 2024 //
GLOBENEWSWIRE
TFF Pharma Ph2 TFF TAC Data for Lung Transplant at ISHLT
29 Apr 2024 //
GLOBENEWSWIRE
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
29 Apr 2024 //
GLOBENEWSWIRE
TFF: More Positive Tacrolimus Inhalation Phase 2 Data
15 Apr 2024 //
GLOBENEWSWIRE
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
28 Mar 2024 //
GLOBENEWSWIRE
TFF Pharmaceuticals Announces Updated Data from the TFF TAC & TFF VORI Programs
27 Mar 2024 //
GLOBENEWSWIRE
TFF Announces Oral Presentation Phase 2 Study of Tacrolimus Inhalation Powder
25 Mar 2024 //
GLOBENEWSWIRE
TFF Pharma Announces Closing of $1.2 Million Registered Direct Offering Priced
22 Mar 2024 //
GLOBENEWSWIRE
TFF Pharmaceuticals Announces Update on Clinical Programs
20 Mar 2024 //
GLOBENEWSWIRE
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering
20 Mar 2024 //
GLOBENEWSWIRE
TFF Pharma to Participate in the 36th Annual Roth Conference “ March 17-19, 2024
14 Mar 2024 //
GLOBENEWSWIRE
TFF Pharma to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder
24 Jan 2024 //
GLOBENEWSWIRE
TFF Pharma Announces Acceptance of Late-Breaking Abstract for Presentation
09 Jan 2024 //
GLOBENEWSWIRE
TFF Pharma Announces Positive Data from Phase 2 Trials of TFF VORI and TFF TAC
19 Dec 2023 //
GLOBENEWSWIRE
TFF Pharmaceuticals to Host Webcast and Conference
18 Dec 2023 //
GLOBENEWSWIRE
TFF Pharmaceuticals Announces Reverse Stock Split
15 Dec 2023 //
GLOBENEWSWIRE
TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors
13 Dec 2023 //
GLOBENEWSWIRE
TFF Pharmaceuticals Appoints Catherine Lee, J.D. to Board of Directors
30 Nov 2023 //
GLOBENEWSWIRE
TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directors
30 Nov 2023 //
GLOBENEWSWIRE
TFF Pharmaceuticals to Participate in the 2023 Benchmark Discovery
27 Nov 2023 //
GLOBENEWSWIRE
TFF Pharmaceuticals Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
TFF Announces Publication Demonstrating Feasibility of Delivery of Monoclonal Antibodies
08 Nov 2023 //
GLOBENEWSWIRE
TFF Pharma to Hold Third Quarter 2023 Financial Results Conference
07 Nov 2023 //
GLOBENEWSWIRE
TFF Pharmaceuticals Congratulates our Scientific Advisory Board Member
02 Oct 2023 //
GLOBENEWSWIRE
TFF Pharmaceuticals to Participate in Upcoming Investor Conferences
28 Sep 2023 //
GLOBENEWSWIRE
TFF Pharma to Participate in H.C. Wainwright 25th Annual Investment Conference
23 Aug 2023 //
GLOBENEWSWIRE
TFF Pharma Announces Closing of $5.7M Public Offering of Common Stock
17 Aug 2023 //
GLOBENEWSWIRE
TFF Pharmaceuticals Prices $5 Million Public Offering of Common Stock
15 Aug 2023 //
GLOBENEWSWIRE
TFF Pharmaceuticals Reports Second Quarter 2023 Financial Results
15 Aug 2023 //
GLOBENEWSWIRE
TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock
14 Aug 2023 //
GLOBENEWSWIRE
TFF Pharmaceuticals to Hold Second Quarter 2023 Financial Results Conference
09 Aug 2023 //
GLOBENEWSWIRE
TFF Pharma and Uniphar Announce the Opening of an Expanded Access Program for Voriconazole
31 Jul 2023 //
GLOBENEWSWIRE
TFF Pharmaceuticals Awarded $2.97 Million to Develop Universal Influenza Vaccine
26 Jun 2023 //
GLOBENEWSWIRE
TFF Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference
23 May 2023 //
GLOBENEWSWIRE
TFF Pharmaceuticals Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
TFF Enters into CRADA with the National Institute of Environmental Health
04 May 2023 //
GLOBENEWSWIRE
TFF Pharmaceuticals Receives Additional Funding from Leidos DARPA PPB Program
01 May 2023 //
GLOBENEWSWIRE
TFF Pharma Reports Fourth Quarter 2022 and Full Year 2022 Financial Results
07 Mar 2023 //
GLOBENEWSWIRE
TFF Pharmaceuticals to Participate in the 35th Annual Roth Conference
06 Mar 2023 //
GLOBENEWSWIRE
TFF Pharma Appoints Harlan Weisman, M.D. as Permanent Chief Executive Officer
08 Feb 2023 //
GLOBENEWSWIRE
TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak as CMO
09 Jan 2023 //
GLOBENEWSWIRE
TFF Pharmaceuticals Announces Leadership Transition
05 Dec 2022 //
GLOBENEWSWIRE
TFF Pharmaceuticals Announces Closing of $12.3 Million Public Offering
29 Nov 2022 //
GLOBENEWSWIRE
TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock
17 Nov 2022 //
GLOBENEWSWIRE
TFF PharmacReports 3Q 2022 Financial Results and Provides Business Update
14 Nov 2022 //
GLOBENEWSWIRE
TFF Pharma to Hold 3Q 2022 Financial and Business Results Conference Call
07 Nov 2022 //
GLOBENEWSWIRE
